PDCD1 and glioblastoma: Although a remarkable survival benefit has been achieved in many solid tumors including melanoma and lung cancer from recent advances in cancer immunotherapy, clinical trials showed that immune checkpoint inhibitors, such as CTLA-4, PD-1, and PD-L1 inhibitors, failed to prolong survival in patients with glioblastoma [2–4].